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INTRODUCTION 
 
 IntraVenous Regional Anaesthesia (IVRA) since its birth in the hands 
of August Bier in 1908 has become a valuable instrument in the repertoire 
of anaesthesia providers. This method enjoyed wide popularity for a time. It 
is not long before simple and reliable techniques for brachial plexus 
developed, and the intravenous method declined in popularity. 
It was revived in 1963 by Holmes, who  used lignocaine because it 
appeared to give more reliable anaesthesia than procaine. With slight 
technical modifications IVRA, today, is an ideal method of providing 
anaesthesia for minor surgical procedures to the extremities performed on 
an ambulatory basis.  It has the advantages of speed of onset, rapid 
recovery, reliability of blockade  & cost effectiveness. 
 Adjuvants to local anaesthetics have greatly expanded the potential 
applications of regional anaesthesia by providing faster onset time, 
inhibition of tourniquet pain, prolonged post-operative anaesthesia and 
improved peri-operative analgesia apart from decreasing risk of local 
anaesthetic toxicity. 
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 In this regard, ketorolac – a parenterally administered NSAID by 
decreasing tissue prostaglandin (PG) synthesis, decrease peri-operative pain 
in combination with LA.  Being a peripherally acting drug, not crossing the 
blood brain barrier in significant degree, it has the specific advantage of 
minimal CNS side effects. 
 Cumulative effects of these agents result in greater patient 
satisfaction, rapid hospital discharge , cost effectiveness and minimal risks. 
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AIMS OF THE STUDY 
1. To prove the effectiveness of ketorolac as an adjuvant in 
intravenous regional anaesthesia 
2. To know the effect of ketorolac on the tourniquet pain & post 
operative analgesia in IVRA 
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REVIEW OF LITERATURE 
1. A systematic review of adjuncts for intravenous regional anaesthesia 
for surgical procedures.  Andrew Choyce MBCHB FRCA and Philip Peng, 
MBBS FRCPC. From the Department of Anaesthesia, King’s college 
Hospital, Denmark Hill, London, UK and the Toronto Western Hospital, 
Canada. 
 The authors tested the use of adjuncts for intravenous regional 
anaesthesia (IVRA) for surgical procedures in terms of their intraoperative 
effects and postoperative analgesia. 
 They concluded that, there is good evidence to recommend NSAIDS 
in general and ketorolac in particular for improving post operative analgesia 
after IVRA.  Clonidine also appears to improve post operative analgesia and 
prolong tourniquet tolerance.  Opioids are disappointing by this route.  Only 
30 mg meperidine has substantial postoperative benefit but at the expense of 
post deflation side effects.  Muscle relaxants improve motor block and aid 
fracture reduction. 
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2. An evaluation of the analgesic efficacy of intravenous regional 
anaesthesia with lidocaine and ketorolac using a forearm versus upper arm 
tourniquet.   Scott s. Reuben, MD., Robert B. Steinberg, MD, PhD, 
Holly Maciolek, RN and Poornachandran Manikantan MD, Department of 
Anaesthesiology, Tuffs University School of Medicine, Massachusetts. 
 In this study, they assessed the analgesic efficacy of administering 
IVRA by administrating lidocaine and ketorolac with either a forearm or 
upper arm tourniquet for outpatient hand surgery.  They concluded that 
forearm tourniquet intravenous regional anaesthesia with 0.5% lidocaine 
and ketorolac provides  both a longer duration of sensory block and 
prolonged postoperative analgesia compared with upper arm IVRA. 
 
3. Local anaesthetic adjuvants for neuraxial and peripheral  blockade – 
James R. Hebl, MD, Department of Anaesthesiology Mayo – clinic, USA. 
 In this study, they studied about various local anaesthetic additives 
such as opioids, alpha – 2 agonists (clonidine), acetylcholine esterase 
inhibitors(neostigmine) and N methyl – D aspartate receptor antagonists 
(Ketamine) and NSAIDS 
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 They demonstrated that more effective postoperative analgesia can be 
achieved when Ketorolac is used in conjunction with lidocaine for IVRA.  
They hypothesized that more effective analgesia was obtained during IVRA 
administration because a higher concentration of ketorolac existed at the 
site of surgical trauma, where inflammatory mediator synthesis occurred. 
 
4. Comparision of wound infiltration with ketorolac  Versus intravenous 
regional anaesthesia with ketorolac for postoperative analgesia following 
ambulatory hand surgery. 
 - Reuben SG, Duprat MM, Tufts University school of Medicine, 
spring field, Massachusetts, USA. 
 The purpose of this study was to assess the analgesic effectiveness of 
ketorolac administered with lidocaine via intravenous regional anaesthesia 
(IVRA) or via wound infiltration following ambulatory hand surgery.  They 
concluded that ketorolac provides similar postoperative analgesia after 
ambulatory hand surgery when administered with lidocaine either by IVRA 
or by wound infiltration. 
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5. Intravenous Regional Anaesthesia using prilocaine and neostigmine 
 A. Turan, B. Karamanlyog M, D. Memis, G. Kaya and Z. Paukcy ; 
Department of Anaesthesiology and Reanimation, Trakya University, 
Turkey. 
 In this study, thirty patients undergoing hand surgery were randomly 
assigned to two groups to receive IVRA.  They have used 0.5 mg of 
neostigmine as a additive.  They found shortened sensory and motor block 
onset times, improved quality of anaesthesia and prolonged sensory and 
motor block recovery times, and prolonged time to first analgesic 
requirement were found in neostigmine group. 
 
6. 0.5 % versus 1.0%  2 – chloroprocaine for Intravenous Regional 
Anaesthesia : A prospective randomized, Double – Blind Trial. 
 Stephan C. Marsch, MD, D Phil, Mathias Sluga, MD, Wolfgang 
studer, MD, Jonas Barandun, MD, Domenic Scharplatz, MD and wolf gang 
Ummentioter MD, From the Departments of Anaesthesia and surgery, 
Switzerland. 
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 In this randomised prospective double – blind study they tested the 
hypothesis that compared with 40 ml chloroprocaine 0.5 %, 40 ml 
chloroprocaine 1 % results in an earlier onset of analgesia duration and 
improves distal tourniquet tolerance during IV reginal anaesthesia.  These 
beneficial effects must be weighed against a fourfold increase in signs of 
systemic local anaesthetic toxicity. 
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INTRAVENOUS REGIONAL ANAESTHESIA 
 
Intravenous regional anaesthesia (IVRA) was first described by 
August Bier in 1908. He observed that when local anaesthetic was injected 
intravenously between two tourniquets on a limb, a rapid onset of 
anaesthesia occurred in the area between the tourniquets and a slower onset 
occurred beyond the distal tourniquet. The technique did not become 
popular until the 1960s when it was reintroduced by Holmes. Today, the 
technique is slightly modified, using either a single or a double tourniquet at 
one site and injecting local anaesthetic as distal as possible to the cuff. The 
double tourniquet is used to increase safety and to reduce tourniquet pain in 
the awake patient, but there is a possibility of accidental deflation of the 
wrong cuff, which may lead to toxic systemic levels of local anaesthetic. 
IVRA is technically simple and does not require specific anatomical 
knowledge. Success rate is 96–100% with a low incidence of side-effects. It 
is a reliable, simple and safe method of providing anaesthesia for minor 
surgical procedures to the extremities if it is administered by experienced 
clinicians 
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Advantages and Disadvantages of intravenous regional anaesthesia 
Advantages : 
 Speed of onset and rapid recovery 
 Reliability (in the absence of local infection and with adequate 
equipment) 
 Muscle relaxation 
 Technical simplicity 
Disadvantages and Complications 
• Poor postoperative analgesia 
• Limited time of surgical anaesthesia ( < 90 minutes) 
• The potential of systemic local anaesthetic toxicity 
• Nerve damage secondary to direct compression by the  tourniquet 
• Compartment syndrome and loss of limb (very rare) 
Mechanisms of action:  
Local anaesthetic diffuses into the small veins surrounding the nerves 
and then into the vasa nervorum and capillary plexus of the nerves, leading 
to a core to mantle (centrifugal) conduction block in the nerves involved. 
Local anaesthetic then diffuses into the small nerves in the skin, blocking 
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their conduction. The tourniquet produces ischaemia, which contributes to 
the analgesic action of the local anaesthetic by blocking nerve conduction 
and motor endplate function. 20 minutes after tourniquet application alone 
there will be analgesia to pinprick without the injection of any local 
anaesthetic. However, the speed of onset and the density of anaesthesia are 
greater with injection of local anaesthetic. 
Indications: 
IVRA is used for surgical interventions on the hand, forearm or elbow 
that will not exceed 1 hour. These include manipulation of forearm 
fractures, excision of wrist ganglia and palmar fasciotomy. IVRA is 
particularly useful for tendon grafting because it enables the surgeon to 
observe movement and tension of the grafted tendon (after deflating the 
tourniquet) before closing the wound (continued anaesthesia with a wrist 
block). IVRA can also be used for surgery on the foot, ankle or lower leg, 
for example for removing plates, screws or foreign bodies. Surgery on the 
elbow or knee is poorly tolerated using IVRA. 
Contraindications are mainly related to tourniquet use. Absolute 
contraindications include sickle cell disease, Raynaud’s disease or 
scleroderma, allergy to local anaesthetics and patient refusal. Relative 
contraindications include severe hypertensive or peripheral vascular 
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disease, local infection, and skeletal muscle disorders or Paget’s disease 
(local anaesthetic may spread to the systemic circulation via venous 
channels in bone). 
Procedure 
Before the procedure the patient should be: 
 starved for 6 hours  
 monitored closely (standard monitoring applied)  
 placed on a tipping trolley  
 adequately informed about the procedure and have consented to it. 
The equipment required for IVRA includes: 
 pneumatic tourniquet (checked for leaks before the procedure) and 
a pressure gauge  
 Esmarch bandage or Rhys-Davis exsanguinator  
 local anaesthetic solution  
 resuscitation equipment and drugs. 
IVRA of the arm:  
A 22 G cannula is placed intravenously as distal as possible in the 
arm to be anaesthetized. Venous access is established in the opposite arm to 
allow administration of fluids or drugs if necessary. The double tourniquet 
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(two tourniquets each 6 cm wide) or a single one (14 cm wide) is applied on 
the arm with generous layers of padding, ensuring that no wrinkles are 
formed and the tourniquet edges do not touch the skin. The arm is 
exsanguinated either by using the Esmarch bandage or a Rhys-Davis 
exsanguinator. If this is impossible, exsanguination can be achieved by 
elevating the arm for 2–3 minutes while compressing the axillary artery. 
The distal tourniquet is inflated to at least 100 mmHg higher than the 
patient’s systolic blood pressure (250–300 mmHg). The proximal 
tourniquet is inflated to the same pressure. After ensuring inflation, the 
distal cuff is deflated. 
Before injecting local anaesthetic it must be confirmed that no radial 
pulse is palpable. The local anaesthetic is then injected slowly. A standard 
volume for injection into the upper limb is 40 ml, which can be increased to 
50 ml in a fit, large adult. If the injection is too rapid, the venous pressure 
may exceed the tourniquet pressure and the local anaesthetic solution may 
escape into the systemic circulation. Surgical anaesthesia is usually 
achieved within 15 minutes. The distal tourniquet, which overlies part of the 
anaesthetized arm, can then be inflated and the proximal one deflated to 
relieve tourniquet pain. 
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The cuff should not be deflated until 20 minutes after local 
anaesthetic injection because systemic toxic doses of local anaesthetic may 
occur. After 20 minutes, 30% of the injected drug is fixed within the tissues 
and is unavailable for immediate release into the systemic circulation. Cuff 
deflation should be performed in cycles with deflation/inflation times of 
less than 10 seconds until the patient no longer exhibits signs of systemic 
toxicity (e.g. tingling of the lips, tinnitus, drowsiness). Severe signs of 
systemic toxicity include bradycardia, hypotension, ECG abnormalities, 
seizures and loss of consciousness. Maximum blood levels of local 
anaesthesia occur within 10 minutes of cuff deflation. Therefore, the patient 
should be monitored closely for 30 minutes following tourniquet release. 
With lignocaine, 2.5–3 mg/kg, and cuff deflation after 10 minutes, blood 
levels have been reported to be less than 2 micrograms/ml. 
If severe CNS intoxication occurs, appropriate resuscitation 
guidelines should be followed. Emergency drugs must be readily available 
and 100% oxygen should be administered. 
IVRA of the leg:  
The basic technique is the same as for the arm but the dose and 
volume of local anaesthetic has to be doubled for IVRA of the leg, which is 
associated with an increased potential for local anaesthetic toxicity. The 
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tourniquet pressure must be higher in the leg (350–400 mmHg), to occlude 
blood flow in the femoral artery. This may increase the occurrence of 
tourniquet pain. Tourniquets may be applied to the thigh (two tourniquets 
about 9 cm wide) or one at the calf (below the head of the fibula) and one at 
the thigh. The latter is for safety in case of distal cuff failure and is not 
usually inflated. 
Choice of drugs 
Many local anaesthetic drugs, with or without additives, have been 
used for IVRA, but 0.5% prilocaine, 3–6 mg/kg, is the drug of choice 
because it has less systemic toxicity and is partially taken up in the lungs 
before reaching the systemic circulation. The usual dose is 40 ml (200 mg) 
without epinephrine. However, the manufacturers have ceased production 
of 0.5% prilocaine. 1% prilocaine remains available and is licensed for 
IVRA, though its stability is not guaranteed if diluted.  If prilocaine is 
unavailable and 0.5% lignocaine, 3 mg/kg, is used. If IVRA is applied to the 
leg a larger volume must be injected (up to 100 ml). Prilocaine can be used 
undiluted (maximum recommended dose is 400 mg in adults) but lignocaine 
is commonly diluted to lower concentrations (e.g. 0.2–0.25%). 
Prilocaine can cause methaemoglobinaemia but unless doses in excess 
of 600 mg are used it is clinically insignificant in most patients. Although 
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one has to be aware that in patients with anaemia or cardiac conditions even 
small amounts of methaemoglobin can significantly impair the oxygen-
carrying capacity of their red blood cells. Intravenous regional anaesthesia 
with prilocaine in these patients should be considered carefully for its 
benefits. 
Other local anaesthetic agents have been used but do not provide 
superior analgesia or more rapid onset of block. Severe toxic reactions and 
death have been observed with bupivacaine and its use is contraindicated. In 
one study, 0.2% ropivacaine was intraoperatively as effective as 0.5% 
prilocaine but postoperative analgesia was prolonged;  
Additives to local anaesthetics have not been consistently shown to 
have an effect during IVRA but may increase the length of postoperative 
analgesia, probably because of a systemic effect following tourniquet 
release. The reported enhancement of IVRA with pethidine, 1 mg/kg, may 
reflect intrinsic local anaesthetic activity of the drug. 
Experiments with the addition of muscle relaxants produced marked 
muscle relaxation but did not augment analgesia. 
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Ketamine alone appears to provide good sensory analgesia but some 
patients lost consciousness and exhibited the typical features of ketamine 
anaesthesia after tourniquet release. 
Many other drugs have been studied, but only the addition of 
clonidine, 150 micrograms, an α 2-agonist, or the non-steroidal anti-
inflammatory drugs ketorolac, 20 mg, or tenoxicam, 20 mg, to the local 
anaesthetic solution appeared to be effective in prolonging postoperative 
analgesia and relieving tourniquet pain. Guanethidine and calcium-channel 
blockers have been evaluated in the context of chronic pain management 
only . 
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TOURNIQUET 
 
Intravenous regional anaesthesia is a method of producing analgesia 
of the distal part of a limb by intravenous injection, while circulation to the 
limb is occluded. 
 Occlusion of the limb was done previously by winding an esmarch 
bandage proximally up the arm. Now occlusion of the limb was achieved by 
pneumatic tourniquet. Unfortunately, the tourniquet is not physiologic and 
is associated with number of disadvantages. 
SITE OF APPLICAION: 
 The upper arm and thigh have sufficient muscle built to distribute the 
cuff pressure evenly and are recommended sites. 
CUFF WIDTH: 
 The American Heart Association concluded that if a 
sphygmomanometer cuff has a width of 20% greater than the diameter of 
the upper arm or 40% of the circumference of the thigh (to a maximum of 
20cm), then the pressure in the underlying central artery will be equal to 
that in the cuff.  Modern silicone cuffs tend to be smaller than this, 
measuring 90mm width( bladder 70mm) for the arm and 105mm(bladder 
75mm) for the leg. 
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 The tissues immediately underlying the cuff should be protected with 
cotton wool. This is not necessary with correctly applied modern silicone 
cuff 
PRESSURE: 
 It was based on the unsedated patient’s blood pressure measured on 
the ward preoperatively. The recommended cuff pressure for the upper limb 
is systolic BP plus 100mmHg and for lower limb twice systolic BP. This 
higher pressure is needed because there is often not enough room above the 
operating site for full sized cuff. 
TOURNIQUET TIME: 
 The recommended time for upper limb is 90minutes. Two hours 
should be regarded as a maximum but this will not be safe for all patients. 
Notify the surgeon about tourniquet time every half an hour. 
CONTRAINDICATIONS: 
 -Sickle cell disease 
 -Raynaud’s disease and other peripheral vascular disease 
 -Tumour or severe infection at the site of application 
 -Severe left ventricular failure 
 -Deep venous thrombosis- Massive total pulmonary embolism has 
been reported. 
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PHYSIOLOGIC CHANGES CAUSED BY LIMB TOURNIQUETS: 
NEUROLOGIC EFFECTS: 
 -Abolition of somatosensory evoked potentials and nerve conduction 
occurs with in 30minutes 
 -Application for more than 60minutes causes tourniquet pain and 
hypertension 
 -Application for more than 2hours may result in postoperative 
neuropraxia 
 -Evidence of nerve injury may occur at a skin level underlying the 
edge of the tourniquet 
MUSCLE CHANGES: 
 -Cellular hypoxia develops with in 8minutes 
 -Cellular creatine level declines 
 -Progressive cellular acidosis occurs 
 -Endothelial capillary leak develops after 2hours 
 -Limb becomes progressively colder 
SYSTEMIC EFFECTS OF TOURNIQUET INFLATION: 
   Arterial and pulmonary artery pressures become elevated, 
although this effect is usually slight to moderate if only one limb is 
occluded 
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SYSTEMIC EFFECTS OF TOURNIQUET RELEASE: 
 -Transient fall in core temperature 
 -Transient metabolic acidosis 
 -Transient fall in central venous oxygen tension 
 -Rapid release of acid metabolites into central circulation 
 -Transient fall in pulmonary and systemic arterial pressures. 
 -Transient increase in end – tidal carbondioxide 
 -Increased oxygen consumption 
TOURNIQUET PAIN: 
 Patients receiving spinal anaesthesia may develop a poorly defined 
aching or burning sensation in the distal extremity about one hour after 
tourniquet inflation. Although the mechanism and neural pathways for this 
severe aching and burning sensation defy precise explanation, unmyelinated 
, slow –conduction C fibres , which are relatively resistant to local 
anaesthetic blockade, probably play a critical role. Even during general 
anaesthesia, tourniquet pain can be revealed by a gradually increasing mean 
arterial blood pressure. The tourniquet pain and its accompanying 
hypertension influenced by many factors including anaesthetic technique 
(IVRA > Epidural> Spinal> GA), intensity and level of block, choice of 
local anaesthetic (hyperbaric spinal with tetracaine > isobaric bupivacaine), 
and supplementation of the block with opioids. Cuff deflation invariably 
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and immediately relieves the sensation of tourniquet pain and its 
hypertension. Systemic opioids has questionable value in relieving 
tourniquet pain. 
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PHARMACOLOGY  OF LIGNOCAINE 
Lignocaine is a synthetic amide-linked anaesthetic of intermediate 
potency and duration.  In 1943 Lofgren synthesized Lignocaine in Sweden. 
First used by Gordh in 1948. 
Lignocaine is the standard to which all other local anaesthetics are 
compared.  It is currently the most widely used local anaesthetic.  In 
addition, it is a popular antiarrythmic.  It can be given by almost any route. 
Mechanism of action : 
 Lignocaine prevent transmission of nerve impulses by inhibiting 
passage of sodium ions through ion-selective sodium channels in the nerve 
membranes.  This slows the rate of depolarization such that the threshold 
potential is not reached and thus action potential is not propagated.  But 
resting membrane potential is not altered.  Lignocaine binds to the inner 
portion receptor (i.e Sodium channel) after entering the cell membrane. 
Physiochemical properties : 
 Molecular weight 234 
 Weak base with a pka 7.6 – 7.8 
 Very stable, not decomposed by boiling, acids or alkalies 
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 It is less lipid soluble than that of Bupivacaine 
Pharmacokinetics : 
Absorption : 
 It is absorbed from the site of application or injection into the blood 
stream.  Rate of absorption depends on the blood flow to the area and use of 
epinephrine. 
Metabolism : 
 Metabolised in liver by oxidative dealkylation to monoethylglycine 
xylidide followed by hydrolysis of this metabolite to xylidide.  Metabolism 
is dependant on hepatic blood flow. 
 Monoethylglycine xylidide has 80% activity of the parent drug. 
 Xylidide has 10% activity of the parent drug. 
 75% of xylidide is excreted in the urine as 4 – hydroxyl – 2,6 –
dimethylaniline. 
Onset of action : 
 Rapid onset of action 
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 Topical anaesthesia  5-10 mins 
 Conduction anaesthesia 
   For small nerves  5-10 mins 
   For large nerves  10-15 mins 
 Intravenous administration 1-2 mins 
Protein binding : 
 It is 70% bound to α 1 acid glycoproteins 
Volume of distribution : 
 91 litres 
Distribution : 
 Lignocaine has a triphasic distribution 
Rapid distribution phase (α)  : 
 In this phase, the drug is distributed to highly vascular regions.  
t ½ α is 1 min. 
Slow disappearance phase (β) : 
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 The drug is distributed to slowly equilibrating tissues. 
 t ½ β is 9.6 min. 
Slow transformation and excretion phase ( δ )  : 
 t ½ is δ is 1.6 hrs 
 Clearance is 0.95 litres per minute 
Availability : 
a) 5% heavy 2 ml ampoules which contain 50 mg of lignocaine / ml 
with 75 mg – 100 mg of dextrose 
b) 2% ligcocaine (xylocard) without preservative – 50 ml vial for 
intravenous use 
c) 2% lignocaine – plain – 30 ml vial –contains methyl and propyl 
paraben as preservative 
d) 4% lignocaine with 1 in 200000 Adrenaline – 30 ml vial. 
e) 4% lignocaine viscus 
f) 4% lignocaine aqueous solution 
g) 10% lignocaine spray 
h) 2% lignocaine Jelly 
i) 2% lignocaine ointment  
j) 5% lignocaine ointment 
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Pharmacodynamics : 
Local actions : 
 Causes nerve blockade with loss of pain and temperature sensation, 
touch, motor power and vasomotor tone in the region supplied by the nerves 
blocked. 
Systemic actions : 
 Result of systemic absorption from the site of administration or 
intravenous administration 
Cardiovascular system : 
 It has a stabilizing effect on the cell membranes of cardiac tissue. 
 Lignocaine depresses myocardial automaticity by antagonizing the 
spontaneous phase IV depolarization and reduces the duration of effective 
refractory period. 
 Myocardial contractility and conduction velocity are depressed at 
higher concentrations. 
 These effects result from direct cardiac muscle membrane changes 
(ie.) cardiac sodium channel blockade. 
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 It stabilizes the membrane of damaged and excitable cells, tending to 
suppress ectopic foci. 
Respiratory system : 
 Lignocaine depresses hypoxic drive (the ventilatory response to low 
PaO2). 
 Apnea can result from phrenic and intercostal nerve paralysis or 
depression of the medullary respiratory center following direct exposure to 
the local anaesthetic agents. 
 Relax bronchial smooth muscle. 
 Intravenous lignocaine may be effective in blocking the reflex 
bronchoconstriction associated with intubation. 
Vascular smooth muscle : 
 Produces vasodilatation 
Central nervous system : 
 Produces a sequence of stimulation followed by depression. Produces 
sedation on intravenous administration. 
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 Intravenous administration decreases cerebral blood flow and 
attenuates the rise in intracranial pressure that accompanies intubation. 
 Infusion of lignocaine is capable of reducing the MAC of volatile 
anaesthetics by 40%. 
Musculoskeletal : 
 Lignocaine is myotoxic leading to lytic degeneration, edema and 
necrosis. 
Haematological : 
 It decreases coagulation and enhances fibrinolysis 
Indications : 
1. For infiltration block, peripheral nerve blocks, epidural, spinal and 
topical anaesthesia & intravenous regional anaesthesia. 
2. Antiarrythmic : 
Lignocaine is a class IB antiarrythmic. 
Ventricular tachyarrythmias 
Arrythmias following acute MI during cardiac surgery 
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  In digitalis toxicity – because it does not worsen AV – block 
3. Prevention or treatment of increases in intracranial pressure during 
intubation 
- antitussive effect may be the reason. 
4. Reflex induced bronchospasm is also attenuated by iv 
administration of lignocaine 
5. Suppresses noxious reflexes such as coughing & sympathetic 
stimulations associated with endotracheal suctioning and 
intubation. 
6. Used as an antiepileptic agent intravenously 
7. Used intravenously as an analgesic for certain chronic pain states 
8. Used as a supplement to general anaetheisa. 
Contraindications : 
 Hypersensitivity 
 Should not be used with vasoconstrictor in digits of hand, feet and 
penis 
 Stokes Adams syndrome, severe degree of heart block 
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Doses : 
Maximum recommended dose : 
 a) Plain  - 3 mg / kg 
 b) with adrenaline- 7 mg / kg 
 c) for reflex suppression  -  1.5 mg / kg  iv. 
Drug interactions : 
β  Blockers : 
 Coadministration of betablockers, increases serum levels of 
lignocaine and its toxicity by decreasing lignocaine’s metabolism. 
Anticonvulsant agents : 
 Increases lignocaine’s metabolism 
Non depolarizing muscle relaxant 
 Blockade is potentiated by lignocaine 
Opioids and  α 2 adrenergic agonists : 
 Potentiate lignocaine’s pain relief 
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Antiarrythmic agents 
 Potentiate the cardiac effects of lignocaine 
Toxicity  : 
 Mostly due to systemic absorption of locally administered lignocaine 
or due to accidental intravenous administration of large doses of lignocaine. 
 The central nervous system is mostly vulnerable. 
Blood levels and symptoms : 
 4 µg / ml  :  Light headedness, tinnitus, circumoral and tongue 
numbness   ( anticonvulsant and antiarrhythmic activity) 
 6 µg / ml :  visual disturbances 
 8 µg / ml  :  muscular twitching 
 10 µg / ml :  convulsions 
 12 µg / ml  :  Unconsciousness 
 15 µg / ml   :  Coma 
 20 µg / ml   :  respiratory arrest 
 26 µg / ml   : cardiovascular collapse 
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Treatment of toxicity : 
 Continuous monitoring of CVS and RS status helps to identify the 
toxicity earlier. 
 If convulsions occur barbiturates or benzodiazepines can be given. 
 Succinylcholine  1 mg / kg to paralyse the patient and aids in 
controlling the seizures. 
 Cardiac toxicity like fibrillation can be treated by defibrillation 
 Ventilatory support – 100 % oxygenation, intubation etc., 
 Maintain B.P. by rapid infusion of I.V. fluids, use of vasopressors and 
put the patient in Trendelenberg’s position. 
 Maintain fluid and electrolyte balance. 
Adverse effects : 
1. Allergic and hypersensitivity reactions 
  Due to the preservative used – methyparaben 
2. CVS : 
 Bradycardia, hypotension 
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PHARMACOLOGY OF KETOROLAC 
 
Ketorolac trimethamine is a non-steroidal anti-inflamatory 
drug(NSAID) in the family of pyrrolo-pyrrolo derivative,  used as an 
analgesic, antipyretic  and anti-inflammatory. Ketorolac acts by inhibiting 
bodily synthesis of prostaglandins. Ketorolac in its oral and intramuscular 
preparations is a racemic mixture of R-(+)(which is the salt 1H-Pyrrolizine-
1-carboxylic acid,5-benzoyl-2,3-dihydro- ketorolac) and S-(-) (which does 
not have the 1H-Pyrrolizine-1-carboxylic acid,5-benzoyl-2,3-dihydro 
group) ketorolac. It is one of the few NSAIDS approved for intravenous 
administration. 
Chemistry 
Ketorolac contains a chiral carbon in the β-position of the propionate 
moiety. As such there are two possible enantiomers of ketorolac with the 
potential for different biological effects and metabolism for each 
enantiomer. 
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Mechanism of action 
The primary mechanism of action responsible for Ketorolac's anti-
inflammatory/antipyretic/analgesic effects is the inhibition of prostaglandin 
synthesis by competitive blocking of the the enzyme cyclooxygenase 
(COX). Like most NSAIDs, Ketorolac is a non-selective cyclooxygenase 
inhibitor.It mainly acts peripheraly than central. 
As with other NSAIDs, the mechanism of the drug is associated with 
the chiral S form. 
Pharmacodynamics: 
 After IM injection maximum plasma concentration of ketorolac was 
achieved with in 45 to 60minutes and the elimination half time is 5hours. 
Protein binding exceeds 99% and clearence of this drug is decreased 
compared to with that of opioids. Clearence is furthur decreased in elderly 
individuals and the dose of the ketorolac less than that given to younger 
patients. Ketorolac  is metobolised principly by glucuronic acid conjugation 
and excreted unchanged in urine. Plasma t ½ is 5-7hours.  Urinary excretion 
accounts for about 90% eliminated drug. 
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AVAILABLE ROUTES: 
Ketorolac avilable as Oral, IM, IV formulations. 
DOSAGE: 
Ketorolac 30mg IM, produces analgesia that is equivalent to 10mg of 
morphine and 100mg of meperidine.15-30mg im or iv every 4-6hours (max. 
90mg/day). Orally it is used in a dose of 10-20mg 6hourly for short term 
management of moderate pain. Continious use for more than 5days is not 
recommended. 
Indications 
Ketorolac is indicated for short-term management of pain mainly, 
postoperative pain and musculoskeletal pain.  It canbe used with opioid 
analgesic in general anaesthesia and as adjuvant for LA in IVRA. 
Contraindications 
Ketorolac is contraindicated against patients with a previously 
demonstrated hypersensitivity to ketorolac, and against patients with the 
complete or partial syndrome of nasal polyps, angioedema, bronchospastic 
reactivity or other allergic manifestations to aspirin or other non-steroidal 
anti-inflammatory drugs (due to possibility of severe anaphylaxis). 
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ADVERSE EFFECTS 
Body system Effects 
General 
Edema. Less frequently, hypersensitivity reactions (such as 
anaphylaxis, bronchospasm, laryngeal edema, tongue edema, 
hypotension), flushing, weight gain, or fever. Very 
infrequently, asthenia. 
Cardio vascular. Hypertension. Less frequently, palpitation, pallor, or syncope.
Dermatologic 
Rash or pruritus. Less frequently, Lyell's syndrome, Stevens-
Johnson syndrome, musculo-papular rash, exfoliative 
dermatitis, or urticaria. 
Gastro intestinal 
Nausea, dyspepsia, gastrointestinal pain, constipation, 
diarrhea, flatulence, gastrointestinal fullness, vomiting or 
stomatitis. Less frequently, peptic ulceration, gastrointestinal 
hemorrhage, gastrointestinal perforation, melena, rectal
bleeding, gastritis, eructation, anorexia, or increased appetite. 
Very infrequently, pancreatitis. 
Hematopoetic 
and lymphatic. 
Purpura. Less frequently, postoperative wound hemorrhage, 
thrombocytopenia, epistaxis, or anemia. Very infrequently, 
leukopenia or eosinophilia. 
Neurological 
Drowsiness, dizziness, headache, sweating, injection site 
pain. Less frequently convulsions, vertigo, tremors, abnormal 
dreams, hallucinations, or euphoria. Very infrequently, 
paresthesia, depression, insomnia, inability to concentrate, 
nervousness, excessive thirst, dry mouth, abnormal thinking, 
hyperkinesis, or stupor 
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Respiratory 
Less frequently, dyspnea, asthma and pulmonary edema. 
Very infrequently, rhinitis or cough. 
Urogenital 
Less frequently, acute renal failure. Very infrequently 
polyuria or increased urinary frequency 
Warnings and precautions 
The most serious risks associated with ketorolac are, as with other 
NSAIDs, gastrointestinal ulcerations, bleeding and perforation; renal events 
ranging from interstitial nephritis to complete renal failure; hemorrhage, 
and hypersensitivity reactions. 
As with other NSAIDs, fluid and solute retention and edema have 
been reported with ketorolac; ketorolac elevates liver protein levels; it also 
inhibits platelet aggregation and may be associated with an increased risk of 
bleeding. 
It should be noted that when administered intraveinously through the 
same IV catheter as Morphine the two drugs have been known to sometimes 
combine to form a precipitate in the IV, which may block the line. Line 
flushing with a syringe of saline can push the blockage through. 
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Cautions 
Ketorolac is not recommended for pre-operative analgesia or co-
administration with anaesthesia because it inhibits platelet aggregation. 
Ketorolac is not recommended for obstetric analgesia because it has 
not been adequately tested for obstetrical administration and has 
demonstrable fetal toxicity in laboratory animals. 
Ketorolac has been co-administered with meperidine and morphine 
without apparent adverse effects. 
Ketorolac is not recommended for long-term chronic pain patients. 
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MATERIALS AND METHODS 
 This is a prospective double blind study conducted at Government 
Rajaji Hospital attached to Madurai Medical College. 
 After approval by the ethical committee 50 patients of ASA grade I & 
II  age between 15-70 years who came for upper limb surgeries which 
lasting for less than 60 minutes were included in this study. 
 Patients with history of allergic to local anaesthetics, sickle cell 
disease, raynaud’s disease, scleroderma, local infection, pagets disease and 
patients with inadequate starvation  <  6 hours and patients who had 
contraindication to ketorolac were excluded from this study.  Preanaesthetic 
evaluation was done. 
 All patients were premedicated with Inj. Midazolam 2 mg  IM  45 
minutes before surgery.  Resuscitation equipment and drugs were kept 
ready.  Initial PR, BP, SPO2 were estimated continuously. 
 A 22 G cannula was placed intravenously as distal as possible in the 
arm to be anaesthetized.  Venous access is established in the opposite arm 
to allow administration of fluids or drugs if necessary.  The double 
tourniquet was applied on the arm with generous layers of padding, 
ensuring that no wrinkles are formed and the tourniquet edges do not touch 
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the skin.  The arm was exsanguinated by using Esmarch bandage.  If this 
was impossible, exsanguination was achieved by elevating the arm for 2-3 
minutes while compressing the axillary artery. 
 The proximal tourniquet was inflated to at least 100 mm Hg higher 
than the patients systolic blood pressure.  Before injecting local anaesthetic, 
radial pulse was palpated and confirmed that there was no pulse.  The local 
anaesthetic is then injected slowly over 90 secs.  A standard volume of 40 
ml of 0.5% lignocaine or 40 ml of 0.5 mg ligcocaine with ketorolac was 
injected. Patients were divided into two groups according to the drug which 
they received.  Group A patients received 40 ml of 0.5% lignocaine and 
group B patients received 40 ml of 0.5% lignocaine with 20 mg of 
ketorolac.  After achieving surgical anaesthesia, the distal tourniquet which 
overlies part of the anaesthetized arm was inflated and the proximal one 
was deflated.  After that the surgeons were allowed to proceed. 
 Intraoperatively PR, BP, SPO2, signs of drug toxicity were monitored 
regularly. If  patient complained of tourniquet pain, they were supplemented 
with Inj. Midazolam IV (In titrated doses, max. upto 2 mg) and  
intercostobrachial N block with local infiltration around the cuff.  The cuff 
was not deflated until 20 minutes after local anaesthetic injection even if 
surgery was completed before 20 minutes.  Cuff deflation was performed in 
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cycles with deflation / inflation times of less than 10 seconds until the 
patient no longer exhibits signs of systemic toxicity.  Patients were 
observed for 30 minutes after surgery. 
Intraoperatively the following parameters were noted : 
 Onset action with sensory and motor 
 PR, BP, SPO2 were monitored regularly at frequent intervals. 
 Duration of surgery  
 Need of supplementation 
 Side effects 
 Duration of blockade after cuff deflation both sensory & motor 
Post operatively the following parameters were noted 
 Time to first analgesic need. 
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OBSERVATION AND RESULTS 
 
 
 In my study totally 50 patients were studied. Patients were 
divided into two groups according to the drug which they received. Group 
A patients received 40 ml of 0.5% lignocaine and group B patients received 
40 ml of lignocaine with ketorolac 20mg. Computer Analysis of Statistical 
data was done utilizing Epidemiological Information Package (EPI 2003) 
developed by World Health Organisation. Frequencies, percentages, mean, 
S.D. and ‘p’ values were calculated using this package. 
 
DEMOGRAPHIC DATA 
Table 1 : Age Distribution 
 
Age Group Study Group Controls 
No. % No. % 
<20 4 16 2 8 
20-29 12 48 11 44 
30-39 4 16 5 20 
40-49 2 8 - - 
50 & above 3 12 7 28 
Total 25 100 25 100 
Mean 
S.D. 
Range 
28.4 
12.5 
10-55 
35.1 
15.7 
16-70 
‘p’ 0.0692 (Not significant) 
 
Comments:  
The difference between the group with respect to age is not 
statistically significant. Hence the groups are comparable with respect to 
age. 
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Table 2 :Comparison between groups with respect to  Sex 
 
Sex Study Group Controls 
No. % No. % 
Male 10 40 12 48 
Female 15 60 13 52 
P 0.7757 (Not significant) 
 
 The difference between the group with respect to sex is not 
statistically significant. Hence the groups are comparable with respect to 
sex. 
 
Table 3 : Comparison between groups with respect to Weight 
 
Weight in kg Study group Control group 
Range 42-64 46-68 
Mean 52.9 55.3 
S.D. 5.8 5.2 
P 0.1443 (Not significant) 
 
 The difference between the group with respect to weight is not 
statistically significant. Hence the groups are comparable with respect to 
weight. 
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Table 4 : Onset of Sensory blockade 
 
Onset of sensory in 
minutes 
Study group Control group 
Range 2-7 2-7 
Mean 3.64 4.28 
S.D. 1.15 1.62 
‘p’ 0.2940 (Not significant) 
 
  The onset of sensory blockade in study group and control group 
were 3.64+/- 2.3mins and 4.28+/- 3.24minutes respectively. Though  the 
effects of ketorolac appears to be superior, the effect was not statistically 
significant. The effects were almost same. 
 
 
Table 5 :Onset of motor blockade  
Blockade motor in 
min 
Study group Control group 
Range 3-11 5-15 
Mean 7.12 9.48 
S.D. 1.66 2.73 
‘p’ 0.0014 (Significant) 
   
 The onset of motor blockade in study group and control group were 
7.12+/- 3.32 and 9.48+/- 5.46minutes respectively which was statistically 
significant. 
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Table 6 : Duration of Surgery 
 
Duration of surgery 
in minutes 
Study group Control group 
Range 32-71 30-76 
Mean 45.72 45.48 
S.D. 10.65 9.88 
‘p’ 0.938 (Not significant) 
 
 The duration of surgery in study group and control were 45.72+/- 21.3 
and 45.48+/- 19.76minutes respectively. The difference between the groups 
with respect to duration of surgery is not statistically significant. Hence the 
groups were comparable with respect to duration of surgery. 
 
Table 7 : Need  of Supplementation in the intraoperative period  
due to tourniquet pain 
 
Supplementation Study Group Controls 
No. % No. % 
Given 6 24 16 64 
Not given 19 76 9 36 
‘p’ 0.0103 (Significant) 
 
 In the study group 24% patients ( 6patients out of 25patietns) need 
supplementation due to tourniquet pain compared to 64%patients (16 
patients out of 25patients) in the control group. The incidence of tourniquet 
pain in the ketorolac group was less and which statistically significant. 
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Table 8 : Duration of blockade after Cuff deflation - sensory 
 
Duration of sensory 
blockade after Cuff 
deflation   
Study group Control group 
Range 3-13 3-7 
Mean 5.28 4.4 
S.D. 2.67 1.22 
‘p’ 0.4263 (Not significant) 
 
Table 9 : Duration of blockade motor in minutes 
 
Duration of motor 
blockade in minutes 
Study group Control group 
Range 5-17 5-11 
Mean 9.04 7.6 
S.D. 3.05 1.55 
‘p’ 0.0933 (Not significant) 
 
 The duration of sensory blockade after cuff deflation in study group 
and control group were 5.28+/- 5.34miutes and 4.4+/- 2.44minutes 
respectively. The duration of motor blockade after cuff deflation in study 
group and control group were 9.04+/-6.1minutes and  7.6+/- 3.1minutes. 
Though the duration of blockade found to be superior than that of control 
group, the difference in the effects between them were not statistically 
significant.   
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Table 10 : Time to first Analgesic (in minutes) 
 
Time of first 
Analgesic (in 
minutes) 
Study Group Controls 
No. % No. % 
<60 1 4 25 100 
61-120 9 36 - - 
121-180 15 60 - - 
>180 - - - - 
Range  
Mean 
S.D. 
85-156 
123.1 
24.7 
11-28 
19.4 
5.5 
‘p’ 0.0001 (Significant) 
 
 The time for first analgesic requirement in study group and control 
group were 123.1+/-49.4miutes and 19.4+/-11miutes respectively. The 
differences between them were statistically significant. The lowest duration 
achieved in ketorolac group was 85minutes and longest duration was 
156minutes. 
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HEAMODYNAMIC PARAMETERS AND SIDE EFFECTS 
 
Table 11 : Mean Arterial Pressure after cuff deflation at 1minute 
 
1" MAP  Study group Control group 
Range 90-111.33 80-104.67 
Mean 109.8 103.9 
S.D. 15.2 6.7 
P 0.2045 (not Significant) 
 
 
Table 12 :  Pulse Rate after cuff deflation at 1minute 
 
1" PR Study group Control group 
Range 62-104 60-94 
Mean 86.2 80.7 
S.D. 12.5 8.1 
P 0.2463 (not Significant) 
 
 The difference between the group with respect to mean arterial 
pressure and pulse rate at 1minute is not statistically significant. Hence the 
groups were comparable with respect to mean arterial pressure and pulse 
rate at 1 minute after cuff deflation. There were no side effects noted in both 
the groups after cuff deflation. 
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 Table 13 : Mean Arterial Pressure after cuff deflation at 5minutes 
 
5" MAP  Study group Control group 
Range 78.33-110.33 70-109.33 
Mean 93.1 87 
S.D. 9.8 6.8 
P 0.3166 (Not significant) 
 
 
Table 14 : Pulse Rate after cuff deflation at 5minutes 
 
 
5" PR Study group Control group 
Range 58-99 58-92 
Mean 80.8 79 
S.D. 12.9 7.9 
P 0.2756 (Not Significant) 
 
 The difference between the group with respect to mean arterial 
pressure and pulse rate which was recorded at 5minutes after cuff deflation 
was not statistically significant. Hence both the groups were comparable. 
There were no side effects noted after cuff deflation in both the groups. 
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DISCUSSION 
   Intravenous regional anaesthesia uses local anaesthetics 
administered to one particular limb by occluding the arm proximally to 
provide conduction blockade.  It must be safe, not threatening or unpleasant 
to the patient, allow adequate surgical access to the operative site, and cause 
as little disturbance as possible to the internal homeostatic mechanisms. 
 Intravenous regional anaesthesia has many advantages. It is  simple, 
reliable with rapid onset and recovery.  Despite these advantages 
intravenous regional anaesthesia has its own limitations like lack of  
postoperative analgesia and tourniquet pain which causes discomfort to the 
patient. In this study, we attempted to eliminate these disadvantages by 
adding ketorolac as an adjuvant.   
Comparison of results: 
In this study both group A (lignocaine only) and group B (lignocaine 
with ketorolac) patients were comparable in respect of age, sex, weight and 
duration of surgery. 
 The onset of sensory blockade was similar in both the groups.  But 
there was rapid onset of motor blockade in ketorolac group in my study. 
This is contrary to the findings of  Andrew choyce et al, who showed that 
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ketorolac added to IVRA produces similar onset profile in both the groups.
 Duration of blockade after cuff deflation, both sensory and motor has 
similar recovery profile. This results correlate with studies conducted by 
Scott S. Reuben et al. 
 Incidence of tourniquet pain which was assessed by supplementation 
during surgery was significantly less in ketorolac group (24%) than 
lignocaine group (64%) which was statistically significant. The p value is 
0.0103. Similar study conducted by   Scott S. Reuben et al, Duprat KM et 
al, James R. Hebel et al shows incidence of tourniquet pain was less with 
when ketorolac as an additive. 
 The duration of post operative analgesia which was assessed by time 
to first analgesic, in ketorolac group is 123.1+/-49.4minutes and lignocaine 
group is 19.4+/- 11 minutes. The p value is 0.0001, p <<< 0.5, which is 
statistically highly significant. The results correlate favourably with the 
studies conducted by Scott S. Reuben et al in which the mean duration of 
analgesia was 701+/- 133 minutes. Other study conducted by Andrew 
choyce et al, the mean duration of analgesia was 624+/-80minutes. 
 Surgical trauma results in release of intracellular contents from 
damaged and inflammatory cells.  Nociceptor stimulation cause a 
neurogenic response with release of mediators such as substance P and 
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neurokinin A.  This results in an “inflammatory soup” containing histamine, 
serotonin, bradykinin and metabolites of the cyclooxygenase and 
lipooxygenase pathways.  Ketorolac inhibit the production of prostaglandins 
from arachidonic acid in phospholipid membranes.  The result is decreased 
afferent nociceptive signals arising from the site of surgery.  Whether 
interfering with the synthesis of inflammatory mediators has a preemptive 
analgesic role in preventing sensitization of nociceptors remains 
controversial. The role of ketorolac in the management of postoperative 
pain is well established.  Clinical studies have demonstrated an enhanced 
analgesic effect from ketorolac when concentrated at a peripheral site 
compared to the systemic administration of the same drug.  This would 
suggest a predominantly peripheral site of action.  It is interesting to note 
that the plasma half-life of ketorolac is four to six hours yet the duration of 
analgesia reached a plateau at over ten hours.  It may be that by 
concentrating the dose of ketorolac at the site of surgery, either as part of 
IVRA or wound infiltration, the resulting analgesic benefit is longer lasting 
than the same dose administered parenterally. Presumably there is a 
persistent drug level in the tissues, and this coupled to the lower dosage 
could result in reduced systemic side effects. 
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 Considering all the above said factors ketorolac in the dose of 20 mg 
can be used as a adjunt for intravenous regional anaesthesia with improved 
duration of postoperative analgesia duration and decreased incidence of 
tourniquet pain. 
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CONCLUSION 
 Ketorolac 20 mg which was added to lignocaine for IVRA provides 
1. Less incidence of tourniquet pain 
2. Increases the duration of post operative analgesia 
3. No significant increase in side effects and there was no 
haemodynamic changes. 
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PROFORMA 
KETOROLAC AS AN ADJUNCT IN IVRA 
Name  :     Age / Sex : 
IP No.  :     Weight : 
Diagnosis :     ASA Risk : 
Surgery  : 
Premedication : 
1. Onset of action  : Sensory : 
    Motor  : 
2. Side effects noted  : 
3. Duration of surgery  : 
Time Pre 5 10 15 20 30 40 60 75 90 120 
HR            
BP            
4. Supplementation : 
5. Duration blockade after cuff deflation : Sensory   : 
          Motor      : 
6. Post operative : 
  Time to first analgesic  : 
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1 Indhirani 21 F 369282 46 Gang Exci 4 7 40  5 9 105 100 94 73 84 
2 Arumugam 20 F 85561 52 Gang Exci 3 6 38 Y 4 10 148 99 69 80 58 
3 Indumathi 31 F 187213 54 Gang Exci 4 6 42  7 9 126 108 88 90 82 
4 Backiyam 30 F 153544 52 Gang Exci 2 3 32  4 7 110 117 102 106 90 
5 Muthuraman 55 M 339880 55 R Radius ORIF 4 9 52 Y 10 17 148 123 94 73 88 
6 Ayerna 23 F 107601 56 Gang Exci 3 6 41  5 6 85 124 101 106 96 
7 Muniyappan 28 M 154870 62 Gang Exci 5 9 40  9 11 156 110 86 86 74 
8 Krishnakumar 16 M 401202 47 Gang Exci 4 7 35  13 16 131 111 72 76 62 
9 Kavitha 30 F 21176 51 Ext.Poi.I TT 5 9 56 Y 4 7 125 106 79 86 72 
10 Pounamma 47 F 20619 42 Gang Exci 4 6 47  4 8 138 93 89 80 80 
11 Ammasi 50 M 169032 54 Gang Exci 5 7 35  11 14 126 106 99 96 94 
12 Gurunathan 55 M 337463 62 RA  FA SSG 3 7 58  3 9 152 100 69 93 64 
13 Selvi 20 F 329078 56 Gang Exci 2 6 43  3 7 106 117 82 106 79 
14 Muthulakshm 20 F 351114 51 ETI Repair 3 8 71  4 9 95 123 102 93 96 
15 Jeyamani 45 F 349412 45 FTI Repair 2 9 61  5 11 111 111 96 96 90 
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16 Chitrakala 21 F 37151 56 Gang Exci 4 8 41  4 7 132 90 96 99 90 
17 Alagar 27 M 248205 58 LFA Exci 3 6 34  5 9 152 98 64 96 60 
18 Balamurugan 17 M 356682 51 C F3-F5 R SSG 4 7 54  5 11 132 93 72 83 66 
19 Mahalakshmi 24 F 2404998 50 Gang Exci 2 5 36  4 8 126 94 86 91 82 
20 Gomathy 35 F 1016979 55 Gang Exci 4 6 43  3 5 114 104 62 90 60 
21 Ahmed 16 M 311385 48 E Rt Ra Exci 4 7 68  4 9 127 113 104 104 99 
22 Murugan 24 M 205282 64 F Radi K-WF 3 6 51  5 7 108 126 90 100 94 
23 Bairavi 18 F 336048 46 Gang Exci 7 11 36  3 5 97 103 86 94 92 
24 Divya 22 F 308025 47 Gang Exci 4 9 42  5 9 138 98 92 92 87 
25 Senthil kumar 21 M 326947 61 X  Rt FA Exci 3 8 47  3 6 145 120 81 110 80 
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1 Pandiyarajan 21 M 203994 46 Gang Exci 4 14 35  3 6 16 80 80 76 80 
2 Kamatchi 30 F 206657 52 Gang Exci 6 15 40  4 7 10 90 79 86 78 
3 Murugesan 20 M 223273 54 Lip elbo Exci 3 7 37  5 7 24 100 84 87 82 
4 Vellaisamy 29 M 199322 52 F BB F ORIF 5 9 76     90 94 83 92 
5 Karupanan 50 M 426816 55 Neu Fib Exci 7 11 47  4 7 14 93 74 83 74 
6 Muthumari 19 F 199641 56 F BB FO Met Ex 3 5 51 Y 7 9 28 104 82 93 80 
7 Shankar 23 F 56168 62 Gang Exci 7 11 41  4 6 19 100 84 80 82 
8 Valarmathy 32 F 196914 47 F T I Repair 3 6 54 Y 4 7 25 93 70 86 71 
9 Deepika 28 F 64255 51 Gang Exci 7 13 30 Y 3 5 17 86 86 90 88 
10 Ravi 35 M 195160 42 Gang Exci 4 9 53 Y 5 7 23 96 90 86 88 
11 Pandiyammal 32 F 158323 54 Gang Exci 3 9 35  5 9 27 88 60 80 58 
12 Veeramani 23 M 181148 62 RA  FA SSG 7 13 56 Y 7 9 11 97 76 86 82 
13 Selvi 23 F 329878 56 Gang Exci 3 9 33  3 5 14 93 76 86 72 
14 Sureshkumar 16 M 190937 51 ETI Repair 4 11 47 Y 4 9 28 93 86 80 82 
15 Karupayee 70 F 404027 45 FTI Repair 3 7 41 Y 4 9 28 100 90 86 90 
16 Mayammal 30 F 194209 56 Gang Exci 5 11 45  3 5 14 97 92 91 81 
17 Rama 65 f 403891 58 LFA Exci 4 9 51 Y 4 8 13 100 64 93 60 
 70
18 Veeralakshmi 27 F 202952 51 C F3-F5 R SSG 3 8 48  5 7 21 100 64 93 60 
19 Bakkarmastan 64 M 438434 50 Gang Exci 7 14 38  5 9 14 94 76 93 76 
20 Krishnan 55 M 197028 55 Gang Exci 4 9 52 Y 5 7 20 93 86 86 80 
21 Ravichandran 24 M 443113 48 E Rt Ra Exci 3 7 41 - 3 9 26 100 80 99 78 
22 Rajkumar 29 M 437328 64 F Radi K-WF 2 6 36 - 3 7 14 80 82 70 80 
23 Muthiah 28 M 232714 46 Gang Exci 3 8 44 Y 4 9 16 96 78 96 76 
24 Maryvictoria 45 F 226944 47 Gang Exci 4 8 50 Y 5 9 12 83 82 83 83 
25 Ramadurai 55 M 437318 61 X  Rt FA Exci 3 8 56 Y 7 9 28 103 86 967 82 
 
 
 
